OpenAI Acquires Drug Development AI Startup Orchestra Bio
· Technology · Axios, TechCrunch
OpenAI acquired Orchestra Bio, a startup building artificial intelligence agents to assist pharmaceutical companies with drug development. The ChatGPT maker completed the acquisition to expand its enterprise footprint into life sciences. Orchestra Bio specializes in automating complex workflows for pharmaceutical researchers managing clinical pipelines. Financial terms of the transaction were not disclosed in the report. The deal positions OpenAI directly against rival artificial intelligence firms targeting the healthcare sector.
Why it matters
Pharmaceutical companies could see accelerated drug discovery timelines as major artificial intelligence providers expand into life sciences technology.
Read the original report — Axios
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.